来自MSN2 天
Do TNF Inhibitors Really Worsen RA-Associated Lung Disease?
Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...
PharmiWeb3 天
CAGE Bio Announces Phase 2b Trial for CGB-500 (1%…
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological ...
CAGE Bio Inc.: CAGE Bio Announces Phase 2b Trial for CGB-500 , a Breakthrough Topical JAK ...
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disord ...
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK ...
SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company ...
The American Journal of Managed Care4 天
Ruxolitinib Combinations in MPNs: Updates From ASH
For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...
pharmaphorum4 天
Aviceda raises $207.5m for eye drug, and other financings
Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...
labiotech4 天
Ten drugs to watch in 2025: will these therapies become blockbusters?
A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...